vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference
November 08, 2023 08:00 ET
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an...
vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer
November 02, 2023 08:00 ET
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an...
vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million
November 01, 2023 08:00 ET
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Nov. 01, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an...
vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update
August 11, 2023 16:30 ET
|
vTv Therapeutics Inc.
HIGH POINT, N.C. , Aug. 11, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an...
vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline
June 16, 2023 08:00 ET
|
vTv Therapeutics Inc.
HIGH POINT, N.C., June 16, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an...
vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals
May 24, 2023 09:00 ET
|
vTv Therapeutics Inc.
HIGH POINT, N.C., May 24, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for...
vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update
May 11, 2023 16:15 ET
|
vTv Therapeutics Inc.
HIGH POINT, N.C., May 11, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for...
vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
March 06, 2023 17:56 ET
|
vTv Therapeutics Inc.
Company preparing to initiate Phase 3 clinical trials of TTP399, an adjunctive therapy to insulin, for the treatment of Type 1 diabetesBiotech industry and Wall Street veteran Steven Tuch appointed...
Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics
February 01, 2023 17:00 ET
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Feb. 01, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for...
vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer
December 13, 2022 08:15 ET
|
vTv Therapeutics Inc.
Steven Tuch, Chief Financial Officer HIGH POINT, N.C., Dec. 13, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the...